Medelinked is the First Application to Feature in BioClinica’s App xChange
News Sep 16, 2015
Medelinked has announced that it will be the first application featured in the BioClinica®, eHealth App xChange™, an alliance channel for disruptive technology innovation across life sciences and healthcare.
Medelinked allows individuals to use mobile technology and the cloud to increase the effectiveness of health care by enabling them to securely build their health profile online and to connect and share with their network of trusted health partners.
Pennsylvania -based BioClinica, a global specialty clinical trials technology and services provider that serves more than 400 pharmaceutical, biotechnology, and device organizations, recently launched the eHealth App xChange. It provides healthcare payers, providers, researchers, regulators and patients with access to transformative applications integrated with and delivered through BioClinica’s eHealth Cloud™.
Leading innovation in regulated clinical trials
BioClinica eClinical President, Mukhtar Ahmed says: "Our App xChange is an incubator and growth engine for niche technology providers and individual app developers, so we welcome Medelinked as the first in a series of new partners as BioClinica continues to lead industry innovation within the regulated clinical trial space."
Ahmed continues: "Medelinked’s presence in the App xChange will enable research communities to ensure unique levels of patient and consumer engagement so accelerating pre- and post-approval research while creating efficiency and quality benefits."
Driving the global shift in how patients and the healthcare industry connect
Ian Gallifant, Medelinked founder and CEO, says: “With this latest development, Medelinked is further driving the global shift in how patients and the healthcare industry connect from early clinical research and trials right through to day-to-day health management. The fact that BioClinica has chosen Medelinked to be the first to feature on its new strategic and disruptive platform is a profound endorsement of the quality and effectiveness of Medelinked’s technology.”
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE